Bone Cancer Drugs Market
Description
Cancer is one of the most prevalent fatal chronic disorders with a high mortality rate due to its extremely invasive nature and prolonged duration of disease. Bone cancer is a type of cancer in which the bone tissues grows in an uncontrollable manner. The market of bone cancer is segmented on the basis of types of bone cancer, such as, primary bone cancer and secondary bone cancer. Primary bone cancer is the type of cancer that originates from rapid and uncontrollable growth of the bone and related tissues. Whereas, Secondary bone cancer is when a cancer that started somewhere else in the body has spread to the bones. The bone cancer is also classified as, osteosarcoma, ewing’s sarcoma, chondrosarcoma, chordomas, fibrosarcoma, and admantinomas.
Market Dynamics
The increasing launches of new drugs and regulatory approvals for bone cancer are expected to drive the market growth during the forecast period. For instance, in May 2020, Bristol Myers Squibb and bluebird bio announced that the companies received a Refusal to File letter from the US Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for idecabtagene vicleucel (ide-cel; bb2121) for patients with heavily pre-treated relapsed and refractory multiple myeloma, which was submitted in March 2020. Furthermore, in April 2016, Advaxis, Inc. received the Fast Tract designation from the US FDA for ADXS-HER2, an Lm Technology immunotherapy product which target HER2 expressing cancers for the treatment of surgically-resectable osteosarcoma. The US FDA’s Fast Tract designation enables the company to accelerate the development process further assisting the patients with rapid and better treatment.
Key features of the study
Market Dynamics
The increasing launches of new drugs and regulatory approvals for bone cancer are expected to drive the market growth during the forecast period. For instance, in May 2020, Bristol Myers Squibb and bluebird bio announced that the companies received a Refusal to File letter from the US Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for idecabtagene vicleucel (ide-cel; bb2121) for patients with heavily pre-treated relapsed and refractory multiple myeloma, which was submitted in March 2020. Furthermore, in April 2016, Advaxis, Inc. received the Fast Tract designation from the US FDA for ADXS-HER2, an Lm Technology immunotherapy product which target HER2 expressing cancers for the treatment of surgically-resectable osteosarcoma. The US FDA’s Fast Tract designation enables the company to accelerate the development process further assisting the patients with rapid and better treatment.
Key features of the study
- This report provides in-depth analysis of the global bone cancer drug market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global bone cancer drug market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Advaxis, Inc., Cellectar Biosciences, Inc., OPKO Health, Inc., Pfizer Inc., Amgen Inc., Novartis AG, Eli Lilly and Company, Debiopharm Group, Merck & Co, Bayer AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical, F. Hoffmann-La Roche Ltd, and Teva Pharmaceutical.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global bone cancer drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bone cancer drug market.
- By Drug Type Insights (Revenue, USD Mn, 2020 - 2032)
- Antimetabolites
- Anthracyclines
- Antibiotics
- Others (RANK ligand inhibitors, etc.)
- By Disease Indication Insights (Revenue, USD Mn, 2020 - 2032)
- Multiple Myeloma
- Osteosarcoma
- Chondrosarcoma
- Ewing’s Sarcoma
- By Distribution Channel Insights (Revenue, USD Mn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Mn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Advaxis, Inc.
- Cellectar Biosciences, Inc.
- OPKO Health, Inc.
- Pfizer Inc.
- Amgen Inc.
- Novartis AG
- Eli Lilly and Company
- Debiopharm Group
- Merck & Co.
- Bayer AG
- Bristol-Myers Squibb Company
- Takeda Pharmaceutical
- F. Hoffmann-La Roche Ltd.
- Teva Pharmaceutical
Table of Contents
204 Pages
- 1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- 2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Disease Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- 3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Market Trends
- Regulatory Scenario
- New Product Launches/Approvals
- Merger, Acquisition and Collaboration Scenario
- PEST Analysis
- PORTER’s Analysis
- 4. Global Bone Cancer Drugs Market, By Drug Type, 2020– 2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021–2032
- Segment Trends
- Antimetabolites
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (USD Mn)
- Anthracyclines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (USD Mn)
- Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (USD Mn)
- Others (RANK ligand inhibitors, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020– 2032, (USD Mn)
- 5. Global Bone Cancer Drugs Market, By Disease Indication, 2020 – 2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021–2032
- Segment Trends
- Multiple Myeloma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020– 2032, (USD Mn)
- Osteosarcoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020– 2032, (USD Mn)
- Chondrosarcoma
- Introduction
- Ewing’s Sarcoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (USD Mn)
- 6. Global Bone Cancer Drugs Market, By Distribution Channel, 2020 – 2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021–2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020– 2032, (USD Mn)
- 7. Global Bone Cancer Drugs Market, By Region, 2020 – 2032, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021–2032
- Segment Trends
- North America
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 –2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020–2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020–2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020–2032, (USD Mn)
- U.S.
- Canada
- Europe
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 –2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020–2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020–2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020–2032, (USD Mn)
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 –2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020–2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020–2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020–2032, (USD Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 –2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020–2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020–2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020–2032, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 –2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020–2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020–2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020–2032, (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 –2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020–2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020–2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2020–2032, (USD Mn)
- North Africa
- Central Africa
- South Africa
- 8. Competitive Landscape
- Company Profiles
- Advaxis, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Cellectar Biosciences, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- OPKO Health, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Amgen Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Novartis AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Eli Lilly and Company
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Debiopharm Group
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Merck & Co.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Bayer AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Bristol-Myers Squibb Company
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Takeda Pharmaceutical
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Hoffmann-La Roche Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Teva Pharmaceutical
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Analyst Views
- 9. Section
- References
- Research Methodology
- About us and Sales Contact
- *Browse 36 market data tables and 26 figures on “Bone Cancer Drugs Market” – Global forecast to 2032
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
